Androgen-independent prostate cancer is an aggressive disease with high angiogenic and metastatic potential. Increased microvessel density and altered invasion properties have previously been described in LNCaP-19, an androgen-independent subline to LNCaP. To characterize the differences in angiogenesis and invasion, the vessels of these tumour xenografts were investigated with immunohistochemistry, and the influence of tumour cells on endothelial cell migration, proliferation and tube formation was studied in vitro. The blood vessels of LNCaP were found to be stabilized by pericytes more frequently than vessels in LNCaP-19. Further, tumour cell invasion was decreased in pericyte-covered blood vessels in both the tumour types. LNCaP-19 displayed an increased potential to induce endothelial cell migration in vitro. In conclusion, pericyte coverage seems to be important for the invasion of tumour cells into blood vessels. Further, LNCaP-19 has lower pericyte coverage and an increased potential to induce endothelial cell migration, which reflects its high microvessel density.
Introduction
Prostate cancer most often develops into an androgenindependent form after primary androgen ablation therapy. For this later stage of prostate cancer, no curative treatment is available and the patients most often die of metastatic disease. Thus, new treatment strategies are urgently needed.
Angiogenesis has been intensively studied in the context of cancer growth. Without induction of angiogenesis the volume of a tumour is limited to a few cubic millimetres. 1 Normally, angiogenesis in the adult is limited to wound healing and cycling of the female genital organs. It is therefore appealing to use angiogenic mechanisms as targets in tumour treatment, because the effects of blocking angiogenesis are mainly restricted to the ongoing angiogenesis in the tumour, and thus, with minimal serious side effects. Tumour vessels often appear abnormal in shape and function, and their endothelial cells are more loosely attached to each other and to the surrounding cells. The stabilizing pericytes that cover normal vessels are often absent or have an abnormal distribution among tumour vessels. 2 These changes in vessel morphology are a result of the angiogenic stimulation from the tumour cells, which is not as well orchestrated as in the development of normal tissues. 3 In prostate cancer, increased angiogenesis, detected as increased microvessel density (MVD), has been correlated both to Gleason grade, prostate-specific antigen relapse and time to progression, 4, 5 as well as metastatic potential. 6 Angiogenesis has been demonstrated to be increased in androgen-independent prostate cancer in experimental animal models and in humans, 7, 8 making these late stage cancers suitable targets for specific antiangiogenic strategies. As the vasculature and angiogenesis are regulated by androgens in the normal prostate as well as in androgen-dependent prostate cancer, 9-11 a changed regulation of angiogenesis could be expected in the androgen-independent state. To be able to design efficient anti-angiogenic drugs, it is necessary to increase the knowledge about regulation of angiogenesis in androgen-independent prostate cancer, especially because a lot of cellular mechanisms are found to be altered during the transition into androgen independency. 12 In the prostate cancer model LNCaP-19, developed in our laboratory, increased MVD was correlated to the switch into androgen independency together with an increased aggressivity in nude mice. 13 During the transition into androgen independency several properties regarding cellular adhesion, invasivity and angiogenesis were changed.
14,15 Surprisingly, the expression of one of the major angiogenic growth factors, vascular endothelial growth factor (VEGF), was not increased, which indicates that other mechanisms also might be involved in the regulation of angiogenesis in this subline. 13, 16 The present study uses LNCaP and LNCaP-19 to investigate pericyte coverage and its influence on tumour invasion into blood vessels in vivo, as well as tumour cells effects on endothelial cells in vitro, to elucidate the differences between androgendependent and androgen-independent prostate cancer.
Materials and methods

Cell culture
The androgen-dependent human prostate cancer cell line LNCaP was obtained from American Type Culture Collection (Manassas, VA, USA). The cells were maintained in RPMI 1640 (PAA Laboratories, Linz, Austria) supplemented with 10% fetal bovine serum (FBS; Gibco, Invitrogen Ltd, Paisley, UK) according to the manufacturer's protocol.
The androgen-independent cell line LNCaP-19 was maintained under the same conditions as the original LNCaP cells, except that the medium contained 10% dextran-charcoal-treated (DCC) FBS instead of normal FBS.
Human microvascular endothelial cells, HMEC-1, were kindly provided by Dr EW Ades and Dr FJ Candal at Center for Disease Control (Atlanta, GA, USA) and routinely cultured in MCDB 131 supplemented with 10% FBS, 20 mg/ml endothelial growth factor and 50 mg/ml hydrocortisone, according to the manufacturer's instructions.
Animal experiments
Male athymic BALB/c-nu mice were obtained from Charles River Laboratories International Inc. (Wilmington, MA, USA). The mice used in the experiment were 10-12 weeks old, and the use of animals was approved by the Animal Ethics Committee in Gö teborg. A total of 2 Â 10 6 LNCaP or LNCaP-19 cells in 150 ml culture medium and 150 ml Matrigel (BD Biosciences, Bedford, MA, USA) were injected subcutaneously into the right flanks of the mice. Animals were killed when the tumours were approximately 1 cm 3 , or after a maximum of 16 weeks. The tumours were harvested and fixed in formalin for paraffin embedding.
Pericyte coverage index and tumour cell invasion
Paraffin sections (4 mm) of tumour tissue samples were deparaffinized and rehydrated. The sections were heated in a microwave oven in 10 mM citrate buffer (pH 6.0) for antigen retrieval. Endogenous peroxidase activity was blocked by 0.3% H 2 O 2 in methanol. The sections were incubated over night at 4 1C with a combination of rat anti-mouse CD34 antibody (ab8158; Abcam, Cambridge, UK), 5 mg/ml, to stain endothelial cells and a monoclonal a-SMA (smooth muscle actin) antibody directly conjugated to alkaline phosphatase diluted 1:20 (A5691; Sigma, St Louis, MA, USA) to detect pericytes. The immunoreaction for CD34 was detected by a biotinylated rabbit anti-rat IgG (DAKO, Copenhagen, Denmark), followed by a peroxidase-labelled ABC reagent (Vector Laboratories Inc., Burlingame, CA, USA) and the chromogen 3,3 0 -diaminobenzidine. The a-SMA immunoreaction was detected with the alkaline phosphatase substrate Vector Red (Vector Laboratories). The sections were counterstained with haematoxylin, dehydrated and mounted.
All CD34-positive entities associated with a-SMApositive cells were counted as pericyte-covered vessels. Stromal and necrotic areas were excluded from the analysis. Five representative fields from each section were evaluated in a light microscope at Â 200 magnification. The mean number of pericyte-covered vessels was divided with the mean total number of vessels in each tumour specimen.
Tumour cell invasion was evaluated in CD34-positive vessels with or without pericyte coverage. The number of vessels containing tumour cells was counted in 10 randomly chosen fields in each section from each tumour (n ¼ 8 for LNCaP and n ¼ 9 for LNCaP-19). Percent invasivity was defined as number of vessels containing tumour cells divided with the total number of vessels with a visible lumen. The experiments were repeated three times.
Endothelial cell migration in vitro
The influence from LNCaP and LNCaP-19 on HMEC-1 migration was investigated in a two-chamber system with an insert with 8 mm pores (Transwell; Corning Life Science, Acton, MA, USA). A total of 5 Â 10 4 LNCaP or LNCaP-19 cells were seeded in 1% DCC-FBS with or without 1 nM of the synthetic androgen R1881 in the lower compartment. After 48 h, 2.5 Â 10 4 HMEC-1 cells were seeded in the inserts in serum-free MCDB 131, and the medium in the lower compartment was changed to serum-free MCDB 131 with or without R1881. After 24 h, the cells on the upper side of the membrane were removed, and the migrated cells on the lower side of the membrane were fixed in methanol and stained with haematoxylin and mounted on glass slides. The number of migrated cells in nine microscopic fields, in the middle of the membrane and perpendicular in four directions, was counted. In each experiment, double or triple inserts were analysed for each cell type. The experiment was repeated five times. Owing to large variations in basal endothelial cell migration between experiments, all values were normalized to the mean migration number in each repetition of the experiment.
Endothelial cell proliferation in vitro
The proliferative effect of LNCaP and LNCaP-19 on HMEC-1 cells was investigated in a two-chamber system with an insert with pores with a diameter of 3 mm (Transwell, Corning Life Science). HMEC-1 cells, 5 Â 10 4 , were seeded in triplicate wells of a 24-well plate in MCDB 131 supplemented with 1% DCC-FBS. LNCaP or LNCaP-19 cells, 2.5 Â 10 4 , were seeded in the inserts in RPMI 1640 supplemented with 1% DCC-FBS in the presence or absence of 1 nM R1881. HMEC-1 cells without the influence from LNCaP or LNCaP-19 cells were used as controls. The experiment was repeated three times.
3 H-thymidine (2 mCi/ml; PerkinElmer Life Sciences Inc., Boston, MA, USA) was added to the wells and after Pericytes, invasion and endothelial migration in LNCaP-19 K Welén et al 24 and 48 h the experiment was aborted by trichloroacetic acid precipitation. After NaOH dissolution, the incorporated 3 H-thymidine was counted in a liquid scintillation counter (Packard, Meriden, CT, USA).
Tube formation
The effect of LNCaP and LNCaP-19 cells on the ability of HMEC-1 to form vessel-like structures in vitro was investigated in the same two-chamber system as described for the proliferation assay. The surface of the lower well was covered with 200 ml growth factorreduced (GFR) Matrigel (BD Biosciences
Statistical analyses
Data are presented as mean ± s.e.m. Mann-Whitney U-test was used to analyse differences between groups. A P-value o0.05 was considered statistically significant.
All statistical analyses were performed using SPSS 12.0 software for Windows.
Results
Pericyte coverage and tumour cell invasion in vivo
To analyse the frequency of pericyte-covered vessels, tumour sections were double-stained with CD34 and a-SMA to detect endothelial cells and pericytes. Cells positive for a-SMA, which were not associated with vessels, were often found within the cancer areas in LNCaP-19, although this phenomenon was rare in LNCaP. The vessels in LNCaP were more frequently covered with pericytes compared to LNCaP-19, 44 and 18%, respectively (Po0.01) (Figure 1 ).
The presence of tumour cells in vessels with a visible lumen, with or without pericyte coverage, was investigated and interpreted as invaded vessels. The influence of pericyte coverage on tumour cell invasion was obvious in both the tumour types. The number of invaded non-covered vessels in LNCaP was 3.4 times higher than the invaded pericyte-covered vessels (Po0.05), and in LNCaP-19 the difference was even larger; 9.5 times higher compared to pericyte-covered vessels (Po0.001) (Figure 2 ).
Tumour cell influence on endothelial cells in vitro
The number of migrated HMEC-1 cells was approximately twice as high in co-culture with LNCaP-19 cells compared to LNCaP cells. The increase in migration was obvious both with (Po0.05) and without (Po0.01) the synthetic androgen R1881. No difference in migration could be detected when compared to control wells without stimulating cancer cells (Figure 3 ).
LNCaP induced a small but statistically significant increase in proliferation, measured as thymidine incorporation, of HMEC-1 cells when compared to the effect of LNCaP-19. The increase was seen both with and without R1881 (10.2% without R1881 (Po0.05) and 14.0% with R1881 (Po0.01)). None of the cell types significantly changed the HMEC-1 proliferation compared to the control wells without stimulating the cells (Figure 4) . HMEC-1 formed nice tube networks after 5-8 h on Matrigel. No statistically significant difference regarding total tube length, or number of branching points was found when comparing the effect of co-culture with LNCaP and LNCaP-19 cells (data not shown).
Discussion
In this study, we have investigated the degree of pericyte coverage on blood vessels of two prostate cancer models to evaluate the role of vessel stabilization for the previously described differences in angiogenesis and invasion. 13, 15 The more angiogenic cell line, the androgen-independent LNCaP-19, displays a lower degree of pericyte-stabilized vessels. In both the tumour types, pericyte coverage limits the invasion of tumour cells into The recruitment of pericytes is one of the final steps in angiogenesis, leading to vessel maturation and stabilization. Consequently, the detachment of pericytes is a prerequisite for angiogenesis to occur, as their presence promotes vessel stability and limits the sensitivity to angiogenic stimuli. Normal vessels are dependent on pericyte coverage to maintain their function, although tumour vessels are able to exist without them. 3 The degree of pericyte coverage varies among different tumour types, with prostate cancer taking an intermediate position with a pericyte coverage of about 30%. 17 The finding of a lower degree of pericyte coverage in LNCaP-19 was not unexpected, because that correlates with an ongoing angiogenesis and thereby with the high MVD previously detected in LNCaP-19 compared to LNCaP. 13 The stabilization of blood vessels by pericytes also correlates with the difference in vessel morphology, where small thin vessels dominate LNCaP-19 tumours in comparison to LNCaP which more often displays larger vessels with a round shape and a more mature and stabilized appearance. 13, 16 The increased MVD of LNCaP-19 has been shown not to depend on an increased expression of VEGF, 13, 16 and no increase of any other obvious inducers of endothelial cell proliferation could be identified in an array-based study.
14 Actually, LNCaP-19 induced a lower endothelial proliferation than LNCaP in this study. However, the slightly higher endothelial proliferation induced by LNCaP cells was statistically significant in vitro, but this does not result in more blood vessels in vivo. In human prostate tumours, the endothelial proliferation index is very low, approximately 2%, 17 but still angiogenesis Pericytes, invasion and endothelial migration in LNCaP-19 K Welén et al seems to be important for the outcome of the tumour. 4 Thus, the increased MVD in LNCaP-19 are likely not related to proliferation of endothelial cells, but might be explained by differences in other mechanisms involved in angiogenesis. The capacity to attract endothelial cells is of vital importance for a tumour to establish a vascular network. The present study demonstrates that LNCaP-19 has a higher capacity to induce endothelial cell migration compared to LNCaP. This difference could be one explanation to the increased MVD detected in the androgen-independent cell line. Further studies are needed to identify the specific mechanism behind this chemotactic property of LNCaP-19.
The angiogenic process and vessel architecture is of importance not only for tumour growth but also for metastatic spread. A crucial step in metastasis is for the tumour cells to invade the vessel through the vessel wall, for further transportation to the target tissue. In this study, we show that stabilization of the vessels, in terms of pericyte coverage, influences the frequency of tumour cell invasion. In both the tumour models, uncovered vessels were more frequently invaded compared to vessels closely associated with pericytes. This relationship has also been shown in experimental models of fibrosarcoma and pancreatic cancer, where the expression of the adhesion factor neural cell adhesion molecule showed to be important for vessel stabilization and the invasion process. 18 In human colon cancer, a relation between pericyte-stabilized vessels and distant metastases have been established, where tumours with a low degree of pericyte-covered vessels formed significantly more metastases. 19 The lower percentage of pericyte coverage in LNCaP-19 tumours, together with the data on increasing tumour cell invasion into blood vessels without pericyte coverage, correlates well with our previously published results on a higher tumour cell invasion in vessels in LNCaP-19 compared to LNCaP. 15 Interestingly, we have unpublished data showing that LNCaP-19 forms distant metastases, including lymph node, lung and skeletal metastases, when implanted orthotopically in severe combined immunodeficient mice, indicating that this model could be a useful tool for studies on prostate cancer metastasis.
The differences in pericyte coverage seen between androgen-dependent and androgen-independent models in the present study may be of importance for the efficacy of anti-angiogenic and traditional cytostatic drugs. Tumour vessels have been shown to have abnormal vessel structure and pericyte coating. 2 A consequence of the improper vessel structure is increased vessel leakage and high interstitial pressure, which could lead to limited diffusion of different drugs into the cancer tissue. 20, 21 There is substantial evidence that tumour vessels are normalized after anti-VEGF treatment, resulting in fewer, but more efficient vessels with proper pericyte coverage, increasing drug delivery to the tissue. [22] [23] [24] Anti-angiogenic strategies targeting both the VEGF and the platelet-derived growth factor (PDGF)-B signalling systems affecting both endothelial proliferation and vessel stabilization have shown to be more efficient on tumour growth than only targeting the VEGF signalling. 25 This strategy disrupts the pericyte coverage and thereby increases the effect of the VEGF blockade, as pericytes induce vessel stability and induce nondependency for VEGF signalling. 26 On the basis of the results of the present study, therapies disrupting pericyte coverage might increase the risk of haematogenous spread of the tumour. However, the effect of the decreased pericyte coverage after anti-PDGF-B treatment on tumour cell invasion and metastasis has not been carefully investigated. Clearly, the combination of anti-angiogenic drugs targeting both the pericytes and endothelial cells need to be optimized regarding the beneficial effects on tumour growth and increased efficiency of other drugs, as well as the detrimental effects of possible increased metastasis.
In conclusion, this study shows that there are differences in pericyte coverage of blood vessel between androgen-dependent and androgen-independent prostate cancer models, which can be of importance for the effects of anti-angiogenic treatment. Further, we demonstrate the influence of pericyte coverage on tumour cell invasion into vessels, a crucial step in haematogenous metastasis, a property which also needs careful consideration when applying combined anti-angiogenic treatment for prostate cancer.
